Literature DB >> 8455905

Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis.

M J O'Doherty1, A G Kettle, C N Eustance, P J Mountford, A J Coakley.   

Abstract

Recommendations for restricting the exposure to radiation of members of the public coming into contact with thyrotoxic patients treated with 131I are currently based on the activity retained by the patient, and not on the doses likely to be received by such individuals. In order to examine whether these current implications of a reduction in this limit to 1 mSv, measurements were made of the dose rates at distances of 0.1, 0.5 and 1.0 m from 60 patients just before they left the nuclear medicine department. These measurements were repeated 1, 3, 6, 8 and 10 days after administration for 30 patients, and the radioactivity in samples of saliva taken on each of these days and secreted in sweat over the first 24 h were also measured. Doses were estimated for administered activities of approximately 200-600 MBq, assuming appropriate values for the times and distances spent near other individuals while travelling, at work, at home and near to young children considered in three age groups (< 2, 2-5 and 5-11 years). Periods of restriction were derived which would reduce these doses to 5 or 1 mSv. For a dose limit of 5 mSv, there is no need to restrict private travel, public transport journeys can last up to 7 h, a patient can return to work immediately, but sleeping with a partner will have to be restricted even for the minimum activity of 200 MBq.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8455905     DOI: 10.1097/00006231-199303000-00003

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131.

Authors:  Tone Cappelen; Jan Frede Unhjem; Anne Lise Amundsen; Gunnhild Kravdal; Ivar Følling
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

2.  Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.

Authors:  S F Barrington; A G Kettle; M J O'Doherty; C P Wells; E J Somer; A J Coakley
Journal:  Eur J Nucl Med       Date:  1996-02

3.  Restrictions following iodine-131 treatment--a time for change or more data required?

Authors:  P J Mountford; M J O'Doherty
Journal:  Eur J Nucl Med       Date:  1994-09

4.  Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism.

Authors:  S F Barrington; P Anderson; A G Kettle; R Gadd; W H Thomson; S Batchelor; P J Mountford; L K Harding; M J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-06       Impact factor: 9.236

5.  The challenges of radioiodine treatment for incontinent paediatric patients with complex care needs.

Authors:  Nathan Dickinson; Jennifer Poveda; Claire Greaves; Charnie Kalirai; Rachel Smith
Journal:  Br J Radiol       Date:  2021-02-15       Impact factor: 3.039

6.  Responsibilities and protection in the use of radioiodine.

Authors:  M J O'Doherty; P J Mountford
Journal:  J R Coll Physicians Lond       Date:  1996 Mar-Apr

7.  Patient external dose rate after 177Lu-DOTATATE therapy: factors affecting its decrease and predictive value.

Authors:  Jules Zhang-Yin; Nadine Guilabert; Thierry Kiffel; Françoise Montravers; Phillip Calais; Jean Lumbroso; Jean-Noël Talbot
Journal:  Int J Med Sci       Date:  2021-05-17       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.